- Home
- TCRX vs UCL Comparison
TCRX vs UCL Comparison
Compare TCRX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | UCL |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 74.5M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCRX | UCL |
|---|---|---|
| Price | $0.99 | $1.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 468.8K | 7.3K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.06 |
| EPS | N/A | ★ 0.12 |
| Revenue | $8,423,000.00 | ★ $85,239,000.00 |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | ★ N/A | $13.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.80 |
| 52 Week High | $2.57 | $4.19 |
Technical Indicators
Market Signals| Indicator | TCRX | UCL |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 48.06 |
| Support Level | $0.91 | $1.51 |
| Resistance Level | $1.04 | $1.67 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.43 | 81.44 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.